The most common side effects in studies were low blood cell counts, namely thrombocytopenia (in 61% of patients, severe in 29%), anemia (in 50%, severe in 25%) and neutropenia (in 30%, severe in 20%). Other, mostly mild to moderate side effects included nausea, fatigue, and constipation. In a study running over 250 days (median), 15% of patients had to permanently discontinue<unk>  due to adverse effects.
Niraparib
Ledipasvir
Umifenovir
Taribavirin
Remdesivir
Bevirimat
Ribavirin
Letermovir